/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Scinai Immunotherapeutics Ltd share price today is $0.73, up -2.67%. The stock opened at $0.7501 against the previous close of $0.75, with an intraday high of $0.7501 and low of $0.723.

style

pb-0

Scinai Immunotherapeutics Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.73 -0.0267(-2.67%) SCNI at 13 Mar 2026 03:09 PM Biotechnology

Lowest Today 0.723

Highest Today 0.7501

Today’s Open 0.7501

Prev. Close 0.75

52 Week High 3.92

52 Week Low 0.61

Day’s Range: Low 0.723 High 0.7501

52-Week Range: Low 0.61 High 3.92

Scinai Immunotherapeutics Ltd Institutional Holdings

Scinai Immunotherapeutics Ltd Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Scinai Immunotherapeutics Ltd Fundamentals

Market Cap 2.39 M

PB Ratio 1.1659

PE Ratio 0.1875

Enterprise Value 9.60 M

Total Assets 13.45 M

Volume 17973

Scinai Immunotherapeutics Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-9286000 -9.3M, FY22:-5796000 -5.8M, FY21:-39978000 -40.0M, FY20:-1385455 -1.4M, FY19:-109194000 -109.2M

Quarterly Revenue Q3/2025:277290 0.3M, Q2/2025:386500 0.4M, Q1/2025:386500 0.4M, Q3/2024:168000 0.2M, Q2/2024:284000 0.3M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-635000 -0.6M, Q1/2025:-635000 -0.6M, Q3/2024:-249000 -0.2M, Q2/2024:-164000 -0.2M

Quarterly Net worth Q3/2025:-2119868 -2.1M, Q2/2025:-2067000 -2.1M, Q1/2025:-1549000 -1.5M, Q3/2024:10455000 10.5M, Q2/2024:-2322000 -2.3M

About Scinai Immunotherapeutics Ltd & investment objective

Company Information Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Organisation Biotechnology

Employees 31

Industry Biotechnology

CEO Mr. Amir Reichman M.B.A., M.Sc.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*